[18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation

[1]  Hanna Cho,et al.  Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation , 2018, The Journal of Nuclear Medicine.

[2]  Keith A. Johnson,et al.  Flortaucipir tau PET imaging in semantic variant primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Luca Passamonti,et al.  [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  Hanna Cho,et al.  18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome , 2017, Neurology.

[5]  P. Svenningsson,et al.  In vivo retention of 18F-AV-1451 in corticobasal syndrome , 2017, Neurology.

[6]  R. Thangavel,et al.  Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..

[7]  D. Holtzman,et al.  Glial contributions to neurodegeneration in tauopathies , 2017, Molecular Neurodegeneration.

[8]  Keith A. Johnson,et al.  Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease , 2017, JAMA neurology.

[9]  David T. Jones,et al.  Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.

[10]  A. Takeda,et al.  In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET , 2016, Neurology.

[11]  J. Trojanowski,et al.  Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.

[12]  Nick C Fox,et al.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.

[13]  C. Jack,et al.  [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.

[14]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[15]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[16]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[17]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[18]  Robert I. Reid,et al.  The evolution of primary progressive apraxia of speech. , 2014, Brain : a journal of neurology.

[19]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[20]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[21]  C. Jack,et al.  Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech , 2012, Brain : a journal of neurology.

[22]  J. Trojanowski,et al.  Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.

[23]  C. Jack,et al.  Imaging correlates of pathology in corticobasal syndrome , 2010, Neurology.

[24]  F. Pasquier,et al.  Prediction of pathology in primary progressive language and speech disorders , 2010, Neurology.

[25]  J. Hodges,et al.  Is the pathology of corticobasal syndrome predictable in life? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[26]  R. Petersen,et al.  Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome , 2009, Movement disorders : official journal of the Movement Disorder Society.

[27]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[28]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[29]  Jennifer L. Whitwell,et al.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.

[30]  J. Duffy.  Apraxia of speech in degenerative neurologic disease , 2006 .

[31]  Joseph James Duffy,et al.  Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia , 2005, Neurocase.

[32]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[33]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[34]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[35]  I Litvan,et al.  The FAB: A frontal assessment battery at bedside , 2000, Neurology.

[36]  R. Petersen,et al.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.

[37]  A. Aronson,et al.  Motor Speech Disorders , 2014 .

[38]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[39]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[40]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.